Neurosigma Inc - Product Pipeline Analysis, 2024 Update

Summary

Neurosigma Inc (Neurosigma) is a life science company that develops and commercializes trigeminal nerve stimulation technologies for neurologic and psychiatric disorders. The company offers treatments for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stress disorder. It also conducts preclinical research and development, and phase clinical trials. Neurosigma offers Monarch eTNS System for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD). The company's trigeminal nerve stimulation has been investigated as a therapy for epilepsy, depression, attention deficit hyperactivity disorder, and post-traumatic stress disorder, Lennox-Gastaut syndrome and traumatic brain injuries, among others. NeuroSigma is headquartered in Los Angeles, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Neurosigma Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company


Neurosigma Inc Company Overview
Neurosigma Inc Company Snapshot
Neurosigma Inc Pipeline Products and Ongoing Clinical Trials Overview
Neurosigma Inc – Pipeline Analysis Overview
Neurosigma Inc - Key Facts
Neurosigma Inc - Major Products and Services
Neurosigma Inc Pipeline Products by Development Stage
Neurosigma Inc Ongoing Clinical Trials by Trial Status
Neurosigma Inc Pipeline Products Overview
Deep Brain Stimulation System - Cachexia
Deep Brain Stimulation System - Cachexia Product Overview
Deep Brain Stimulation System - Obesity
Deep Brain Stimulation System - Obesity Product Overview
DELTA Stent
DELTA Stent Product Overview
Micropatterned TFN Stent
Micropatterned TFN Stent Product Overview
Monarch eTNS System - Autism Spectrum Disorder (ASD)
Monarch eTNS System - Autism Spectrum Disorder (ASD) Product Overview
Monarch eTNS System - Autism Spectrum Disorder (ASD) Clinical Trial
Monarch eTNS System - Depression
Monarch eTNS System - Depression Product Overview
Monarch eTNS System - Epilepsy
Monarch eTNS System - Epilepsy Product Overview
Monarch eTNS System - Lennox-Gastaut Syndrome
Monarch eTNS System - Lennox-Gastaut Syndrome Product Overview
Monarch eTNS System - Post-Traumatic Stress Disorder
Monarch eTNS System - Post-Traumatic Stress Disorder Product Overview
Monarch eTNS System - Traumatic Brain Injury
Monarch eTNS System - Traumatic Brain Injury Product Overview
Next-Generation eTNS System
Next-Generation eTNS System Product Overview
sTNS System - Epilepsy
sTNS System - Epilepsy Product Overview
Thin Film Nitinol Flow Diverting Stent
Thin Film Nitinol Flow Diverting Stent Product Overview
Neurosigma Inc - Key Competitors
Neurosigma Inc - Key Employees
Neurosigma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Neurosigma Inc, Recent Developments
Jan 22, 2025: NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
Jan 13, 2025: Clinical Trial of Neurosigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment
Dec 11, 2024: New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry
May 09, 2024: Neurosigma Announces Acceptance into 2024 Cohort of the Kidsx Accelerator Program
May 09, 2024: NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
Jan 18, 2024: NeuroSigma gets green light from FDA for ADHD wearable
Nov 07, 2023: NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
Mar 01, 2023: NeuroSigma announces new telehealth option for patients and caregivers interested in eTNS for pediatric ADHD
Jan 31, 2023: NeuroSigma announces strategic digital marketing partnership with Data360
Nov 08, 2022: NeuroSigma announces that enrollment commences in two large, double-blind trials of eTNS for Pediatric ADHD
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Neurosigma Inc Pipeline Products and Ongoing Clinical Trials Overview
Neurosigma Inc Pipeline Products by Equipment Type
Neurosigma Inc Pipeline Products by Indication
Neurosigma Inc Ongoing Clinical Trials by Trial Status
Neurosigma Inc, Key Facts
Neurosigma Inc, Major Products and Services
Neurosigma Inc Number of Pipeline Products by Development Stage
Neurosigma Inc Pipeline Products Summary by Development Stage
Neurosigma Inc Ongoing Clinical Trials by Trial Status
Neurosigma Inc Ongoing Clinical Trials Summary
Deep Brain Stimulation System - Cachexia - Product Status
Deep Brain Stimulation System - Cachexia - Product Description
Deep Brain Stimulation System - Obesity - Product Status
Deep Brain Stimulation System - Obesity - Product Description
DELTA Stent - Product Status
DELTA Stent - Product Description
Micropatterned TFN Stent - Product Status
Micropatterned TFN Stent - Product Description
Monarch eTNS System - Autism Spectrum Disorder (ASD) - Product Status
Monarch eTNS System - Autism Spectrum Disorder (ASD) - Product Description
Monarch eTNS System - Autism Spectrum Disorder (ASD) - A Study to Evaluate Efficacy of Monarch eTNS System as a Novel Treatment in Pediatric Subjects with Autism Spectrum Disorder (ASD)
Monarch eTNS System - Depression - Product Status
Monarch eTNS System - Depression - Product Description
Monarch eTNS System - Epilepsy - Product Status
Monarch eTNS System - Epilepsy - Product Description
Monarch eTNS System - Lennox-Gastaut Syndrome - Product Status
Monarch eTNS System - Lennox-Gastaut Syndrome - Product Description
Monarch eTNS System - Post-Traumatic Stress Disorder - Product Status
Monarch eTNS System - Post-Traumatic Stress Disorder - Product Description
Monarch eTNS System - Traumatic Brain Injury - Product Status
Monarch eTNS System - Traumatic Brain Injury - Product Description
Next-Generation eTNS System - Product Status
Next-Generation eTNS System - Product Description
sTNS System - Epilepsy - Product Status
sTNS System - Epilepsy - Product Description
Thin Film Nitinol Flow Diverting Stent - Product Status
Thin Film Nitinol Flow Diverting Stent - Product Description
Neurosigma Inc, Key Employees
Neurosigma Inc, Subsidiaries
Glossary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings